Bifeprunox

Bifeprunox (INN; code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D₂ receptor agonism with serotonin receptor agonism.^[1] It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.^[2]

Bifeprunox

Clinical data
ATC code	none
Identifiers
IUPAC name 7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one
CAS Number	350992-10-8 N
PubChem CID	208951
ChemSpider	181044 Y
UNII	AP69E83Z79
ChEMBL	ChEMBL218166 Y
CompTox Dashboard (EPA)	DTXSID80188592
Chemical and physical data
Formula	C24H23N3O2
Molar mass	385.467 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC5
InChI InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28) Y Key:CYGODHVAJQTCBG-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.^[3] An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.^[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."^[5]

Pharmacodynamics

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

• Aripiprazole
• Pardoprunox